Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

89bio, Inc. - Common Stock (NQ: ETNB )

7.730 -0.150 (-1.90%)
Streaming Delayed Price Updated: 12:34 PM EST, Dec 30, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about 89bio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Why Is 89bio (ETNB) Stock Up 34% Today?
89bio (ETNB) stock is taking off on Wednesday after the company posted results from a Phase 2b clinical trial of pegozafermin. 
Via InvestorPlace
89bio Rockets 30% — And Akero Dives — On A Scorching Battle In Liver Disease
The battle pits 89bio and Akero in nonalcoholic steatohepatitis. 
Via Investor's Business Daily
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
89bio’s Phase 2b ENLIVEN Trial of Pegozafermin in Nonalcoholic Steatohepatitis (NASH) Achieved High Statistical Significance on Both Primary Histology Endpoints with Weekly (QW) and Every-Two-Week (Q2W) Dosing at 24 Weeks
From 89bio, Inc.
Via GlobeNewswire
Charles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
HC Wainwright & Co. cut the price target for 89bio, Inc. (NASDAQ: ETNB) from $27 to $25. HC Wainwright & Co. analyst Ed Arce maintained a Buy rating. 89bio shares fell 5.2% to trade at $11.80 on... 
Via Benzinga
Analyst Ratings for 89bio
Via Benzinga
7 Analysts Have This to Say About 89bio
89bio (NASDAQ:ETNB) has observed the following analyst ratings within the last quarter: 
Via Benzinga
89bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Presents New Analysis of Data from Phase 2 ENTRIGUE Trial of Pegozafermin in Patients with Severe Hypertriglyceridemia (SHTG) at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via GlobeNewswire
DraftKings To Rally Around 38%? Here Are 10 Other Analyst Forecasts For Tuesday
Wells Fargo boosted the price target for Deere & Company (NYSE: DE) from $485 to $510. Wells Fargo analyst Seth Weber maintained an Overweight rating on the stock. Deere shares fell 0.5% to $431.08 in... 
Via Benzinga
89bio to Present Additional Pegozafermin Data in Severe Hypertriglyceridemia from Phase 2 ENTRIGUE Study at American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology
From 89bio, Inc.
Via GlobeNewswire
89bio to Participate in the SVB Securities Global Biopharma Conference
From 89bio, Inc.
Via GlobeNewswire
89bio Provides Business Update and Outlook for 2023
From 89bio, Inc.
Via GlobeNewswire
20 Favorite Biotech & Medical Stocks For 2023
The way these stocks are setting up, many of them look great and will be at the forefront this coming year. 
Via Talk Markets
US Stocks Slightly Lower; Nasdaq Down 100 Points
U.S. stocks traded slightly lower this morning, with the Nasdaq Composite dropping around 100 points on Monday. 
Via Benzinga
Why Cosmos Health Shares Are Trading Lower By Around 60%? Here Are 79 Stocks Moving In Monday's Mid-Day Session
Gainers Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) shares jumped 259% to $229.35 after the company announced resmetirom achieved both primary endpoints in NASH and liver fibrosis trial. 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
89bio Announces Publication of Results of Phase 1b/2a Study of Pegozafermin for the Treatment of NASH in The Lancet Gastroenterology & Hepatology
From 89bio, Inc.
Via GlobeNewswire
89bio Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From 89bio, Inc.
Via GlobeNewswire
89bio Presents Additional Exploratory Analyses from the Phase 1b/2a NASH Study of Pegozafermin at AASLD The Liver Meeting® 2022
From 89bio, Inc.
Via GlobeNewswire
ServiceNow, Teladoc Health And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded mostly higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
$9 Million Bet On 89bio? 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
AVEO Pharmaceuticals, Akouos And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
U.S. stock futures traded higher this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
89bio to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference
From 89bio, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
  
Via Benzinga
Analyst Ratings for 89bio
Over the past 3 months, 7 analysts have published their opinion on 89bio (NASDAQ:ETNB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's... 
Via Benzinga
Why Comera Life Sciences Shares Jumped 101%; Here Are 74 Biggest Movers From Yesterday
Gainers Akero Therapeutics, Inc. (NASDAQ: AKRO) shares jumped 136.8% to settle at $29.05 on Tuesday after the company's Phase 2b HARMONY study met its primary endpoint for both the 50mg and 28mg EFX... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
  
Via Benzinga
Why Amazon, Microsoft, Apple Shares Are Trading Lower, Here Are 50 Stocks Moving In Tuesday's Mid-Day Session
Gainers NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 186% to $47.69 as the stock started trading on a 1-for-30 reverse split basis. 
Via Benzinga
US Stocks Open Lower After Inflation Report, Dow Dips 700 Points
U.S. stocks traded sharply lower this morning, following the release of inflation data for August 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.